Autres langues Immatics N.V.

Actions

IMTX

NL0015285941

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 18:27:06 18/08/2026			Varia. 5j.	Varia. 1 janv.
9,025 ^USD	-2,43%		-7,38%	-14,00%

13:16	Immatics : perte nette en repli au deuxième trimestre sur fond de hausse du chiffre d'affaires	MT
13:10	Flash résultats (IMTX) : Immatics publie un chiffre d'affaires de 9,1 millions d'euros au T2, contre un consensus FactSet de 10,4 millions d'euros	MT

Autres langues

13:16	Immatics' Q2 Net Loss Narrows as Revenue Rises
13:10	Earnings Flash (IMTX) Immatics Posts Q2 Revenue 9.1M Euros, vs. FactSet Est of 10.4M Euros
13:09	Earnings Flash (IMTX) Immatics Posts Q2 Net Loss 0.46 Euros a Share, vs. FactSet Est of 0.45 Euros Loss
13:07	Immatics: Q2 Earnings Snapshot
13:04	Immatics N : Announces Second Quarter 2026 Financial Results and Business Update
13:00	Immatics Announces Second Quarter 2026 Financial Results and Business Update
17/07	Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
15/06	Kalender der Dividendenausschüttungen und Hauptversammlungen vom 15. bis 19. Juni 2026
01/06	Immatics N.V. Announces Updated Clinical Data For IMA203CD8, IMA401, And Anzu-Cel PRAME Cell Therapies
01/06	Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
01/06	Immatics Presents Clinical Activity and Response Dynamics of Anzu-Cel Prame Cell Therapy At 2026 Asco Annual Meeting
31/05	Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
31/05	Immatics N.V. Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
31/05	Immatics N : 2026 ASCO Immatics #11516 anzu-cel IMA203CD8 SynovialSarcoma
30/05	Immatics presents clinical activity of Ima203cd8 Prame cell therapy in hard-to-treat gynecologic cancers
30/05	Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
30/05	Immatics N.V. Presents Clinical Activity Of IMA203CD8 PRAME Cell Therapy In Hard-To-Treat Gynecologic Cancers And Synovial Sarcoma
12/05	Immatics Q1 Loss Widens, Revenue Falls
12/05	Earnings Flash (IMTX) Immatics Posts Q1 Revenue 7.6M Euros, vs. FactSet Est of 8.5M Euros
12/05	Earnings Flash (IMTX) Immatics Posts Q1 Net Loss 0.43 Euro a Share, vs. FactSet Est of 0.45 Euro Loss
12/05	Immatics: Q1 Earnings Snapshot
12/05	Immatics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026
12/05	Immatics Announces First Quarter 2026 Financial Results and Business Update
21/04	Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
17/04	Immatics N : PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma